BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower multiple applied to the firm’s 2025 EPS forecast due to weaker earnings visibility and compression in the group average P/E multiple from tariffs and also drug pricing concerns. Ahead of the company’s Q1 report, the firm updated its U.S. Eylea estimates for the impact from the patient assistance funds closing, the analyst noted.
https://www.tipranks.com/news/the-fly/regeneron-price-target-lowered-to-547-from-575-at-bofa
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.